HRS-7576

HRS-7576 is an investigational small molecule being developed by Tuojie Biotech, a subsidiary of Jiangsu Hengrui Pharmaceuticals, for the treatment of psoriasis. It is currently in the early stages of development, identified in the company's pipeline as being in the early target discovery or preclinical phase. While specific mechanistic details are often proprietary in early-stage pipelines, HRS-7576 is part of a broader effort by Tuojie and Hengrui to develop targeted oral therapies for autoimmune and inflammatory skin diseases, potentially targeting pathways such as RORγt or other key mediators of the IL-17/IL-23 axis.